BeBetter Med Inc. (SHA:688759)

Market Cap	17.83B
Revenue (ttm)	n/a
Net Income	-153.08M
EPS	-0.40
Shares Out	450.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,401,440
Average Volume	3,406,128
Open	40.10
Previous Close	40.30
Day's Range	38.98 - 40.10
52-Week Range	27.53 - 57.47
Beta	n/a
RSI	50.87
Earnings Date	Apr 24, 2026

About BeBetter Med

BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a ...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Country: China
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688759